5 filing types
Recent SEC activity for UNH, refreshed on the regular ingestion cadence.
Free source-linked SEC filing history for UnitedHealth Group Incorporated (UNH). Browse recent 10-K, 10-Q, and 8-K filings with direct SEC source links, filing dates, and signal summaries.
Last checked against SEC EDGAR 2026-10-22 14:16 UTC. 25 filings shown, each linked to its SEC source.
Values come from the XBRL data UnitedHealth filed with the SEC. Each number links to the filing it was reported in. Hover a value to see the XBRL concept and accession number.
| Metric | Latest fiscal year: FY2025 (ended 2025-12-31) | Prior fiscal year: FY2024 (ended 2024-12-31) | Latest quarter: 2026-04-01 to 2026-06-30 |
|---|---|---|---|
| Revenue | $447.6B | $400.3B | $112.0B |
| Net income | $12.1B | $14.4B | $5.5B |
| Diluted EPS | $13.23 | $15.51 | $6.04 |
| Operating cash flow | $19.7B | $24.2B | n/a |
| Cash and equivalents | $24.4B | $25.3B | $28.6B |
| Total assets | $309.6B | $298.3B | $309.7B |
Quarter values cover the three months reported in the latest 10-Q, shown only when it is newer than the fiscal year. Cash-flow totals are reported year-to-date in 10-Qs, so no quarter value is shown for them.
Common-stock transactions reported on SEC Form 4 by UnitedHealth directors, officers and 10% owners. Each row links to its Form 4 on EDGAR. Value is shares × reported price, shown for open-market buys and sales only; for option exercises the price is the exercise price.
| Date | Insider | Transaction | Shares | Price | Value | Owned after | Form 4 |
|---|---|---|---|---|---|---|---|
| 2026-10-01 | Noseworthy John H Director | Grant or award | +240 | $0.00 | n/a | 7,902 | Filed 2026-10-05 |
| 2026-10-01 | MONTGOMERY RICE VALERIE MD Director | Grant or award | +257 | $0.00 | n/a | 8,180 | Filed 2026-10-05 |
| 2026-10-01 | MCNABB FREDERICK WILLIAM III Director | Grant or award | +291 | $0.00 | n/a | 15,810 | Filed 2026-10-05 |
| 2026-10-01 | Gottlieb Scott Director | Grant or award | +257 | $0.00 | n/a | 921 | Filed 2026-10-05 |
| 2026-10-01 | Gil Kristen Director | Grant or award | +240 | $0.00 | n/a | 2,867 | Filed 2026-10-05 |
| 2026-10-01 | GARCIA PAUL R Director | Grant or award | +155 | $0.00 | n/a | 4,077 | Filed 2026-10-05 |
| 2026-10-01 | GARCIA PAUL R Director | Grant or award | +103 | $0.00 | n/a | 4,180 | Filed 2026-10-05 |
| 2026-10-01 | FLYNN TIMOTHY PATRICK Director | Grant or award | +262 | $0.00 | n/a | 11,205 | Filed 2026-10-05 |
| 2026-10-01 | Baker Charles D. Director | Grant or award | +257 | $0.00 | n/a | 2,668 | Filed 2026-10-05 |
| 2026-09-22 | MCNABB FREDERICK WILLIAM III Director | Grant or award | +57 | $0.00 | n/a | 15,519 | Filed 2026-09-24 |
| 2026-09-22 | Stankiewicz Dennis Andrew Chief Accounting Officer | Grant or award | +51 | $0.00 | n/a | 10,109 | Filed 2026-09-24 |
Recent SEC activity for UNH, refreshed on the regular ingestion cadence.
Direct SEC filing and index links keep the page auditable instead of asking readers to trust a black-box summary.
Deterministic scores and reasons help prioritize filings that deserve a closer human review.
Start with the latest filing source, then compare the form type against the context below. Use signal scores as triage, not advice: high scores mean “review sooner,” not “buy or sell.”
Current report for material events such as leadership changes, deals, earnings releases, or governance updates.
SEC filing that may contain material company updates worth verifying at the source.
Quarterly report with fresh operating results, liquidity notes, and risk-factor updates.
Proxy statement with board, executive compensation, shareholder vote, and governance details.
Annual report with audited financials, risk factors, business updates, and management discussion.
UnitedHealth Group Incorporated is tracked here as a health insurance and services company. Use the free filing trail to review source documents before deciding whether paid watchlist delivery is useful.
Medium-priority 8-K: 8-K: Results of Operations and Financial Condition (Item 2.02). Useful for a routine company watchlist review.
Verify at SEC source →Medium-priority 8-K: 8-K: Regulation FD Disclosure (Item 7.01). Useful for a routine company watchlist review.
Verify at SEC source →Medium-priority 10-Q: Quarterly report (10-Q) for the period ended 2026-06-30. Useful for a routine company watchlist review.
Verify at SEC source →8-K: Results of Operations and Financial Condition (Item 2.02)
Form 4: insider transaction report
Form 4: insider transaction report
Form 4: insider transaction report
Form 4: insider transaction report
Form 4: insider transaction report
Form 4: insider transaction report
Form 4: insider transaction report
Form 4: insider transaction report
Form 4: insider transaction report
Form 4: insider transaction report
8-K: Regulation FD Disclosure (Item 7.01)
Quarterly report (10-Q) for the period ended 2026-06-30
8-K: Results of Operations and Financial Condition (Item 2.02)
8-K: Submission of Matters to a Vote of Security Holders (Item 5.07)
8-K: Regulation FD Disclosure (Item 7.01)
Quarterly report (10-Q) for the period ended 2026-03-31
Proxy statement (DEF 14A)
8-K: Results of Operations and Financial Condition (Item 2.02)
8-K: Regulation FD Disclosure (Item 7.01)
8-K: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers (Item 5.02)
Annual report (10-K) for the fiscal year ended 2025-12-31
Quarterly report (10-Q) for the period ended 2025-09-30
Quarterly report (10-Q) for the period ended 2025-06-30
Annual report (10-K) for the fiscal year ended 2024-12-31
The company page stays free. Paid alerts cover watchlist matching, email delivery, dedupe, and future integrations.